BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feng GS, Hanley KL, Liang Y, Lin X. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology 2021;73 Suppl 1:104-14. [PMID: 32715491 DOI: 10.1002/hep.31479] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang X, Zhang J, Gao F, Fan S, Dai L, Zhang J. KPNA2-Associated Immune Analyses Highlight the Dysregulation and Prognostic Effects of GRB2, NRAS, and Their RNA-Binding Proteins in Hepatocellular Carcinoma. Front Genet 2020;11:593273. [PMID: 33193737 DOI: 10.3389/fgene.2020.593273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Zheng Q, Yang Q, Zhou J, Gu X, Zhou H, Dong X, Zhu H, Chen Z. Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions. Cancer Cell Int 2021;21:330. [PMID: 34193146 DOI: 10.1186/s12935-021-02033-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Valenti L, Pedica F, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00337-6. [PMID: 34294580 DOI: 10.1016/j.dld.2021.06.023] [Reference Citation Analysis]
4 Silva L, Egea J, Villanueva L, Ruiz M, Llopiz D, Repáraz D, Aparicio B, Lasarte-Cia A, Lasarte JJ, Ruiz de Galarreta M, Lujambio A, Sangro B, Sarobe P. Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses Against Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3397. [PMID: 33207844 DOI: 10.3390/cancers12113397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kaps L, Schuppan D. Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. Cells 2020;9:E2027. [PMID: 32899119 DOI: 10.3390/cells9092027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
6 Ocker M, Mayr C, Kiesslich T, Stintzing S, Neureiter D. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers (Basel) 2021;13:1558. [PMID: 33805268 DOI: 10.3390/cancers13071558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shi Q, Meng Z, Tian XX, Wang YF, Wang WH. Identification and validation of a hub gene prognostic index for hepatocellular carcinoma. Future Oncol 2021;17:2193-208. [PMID: 33620260 DOI: 10.2217/fon-2020-1112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Xue C, Gu X, Li L. Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma. Cancer Cell Int 2021;21:471. [PMID: 34488768 DOI: 10.1186/s12935-021-02183-5] [Reference Citation Analysis]
9 Dolladille C, Akroun J, Morice PM, Dompmartin A, Ezine E, Sassier M, Da-Silva A, Plane AF, Legallois D, L'Orphelin JM, Alexandre J. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J 2021:ehab618. [PMID: 34529770 DOI: 10.1093/eurheartj/ehab618] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yang S, Cheng Y, Wang X, Wei P, Wang H, Tan S. Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy. Front Genet 2021;12:777931. [PMID: 34899862 DOI: 10.3389/fgene.2021.777931] [Reference Citation Analysis]
11 He X, Sun H, Jiang Q, Chai Y, Li X, Wang Z, Zhu B, You S, Li B, Hao J, Xin S. Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4. Front Oncol 2021;11:735447. [PMID: 34381736 DOI: 10.3389/fonc.2021.735447] [Reference Citation Analysis]